Get Support

Learn Mode

AMGN - Amgen Inc

294

$352.65

$0.80 (0.227%)

4/1/26, 3:26 PM

3.66/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

AMGN

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$190.61B

Industry

Biotechnology

EPS (TTM)

$14.20

P/E (TTM)

24.72

Div & Yield

$10.08 (2.86%)

FCF Payout Ratio

67.26%

P/S (TTM)

5.19

P/B

22.02

Diluted Shares

543.00M

Ex-Dividend

2026-05-15

Next Earnings

04-29

Forward P/E

15.24

Payout Ratio

70.66%

P/FCF (TTM)

23.53

FCF Yield

4.25%

Earnings Yield

4.05%

52 Week Range

Score Card

Explore Scores Tab

3.66

Good

Amgen Inc has grown revenue at 9.95% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 22.04%, which suggests the company is very profitable.

Valuation Model

Key Score

3.00

Average

Management

5.00

Very Good

Growth

5.00

Very Good

Profitability

4.00

Good

Fin. Health

5.00

Very Good

Dividends

1.00

Very Bad

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form ARS

Unknown Form Type

Filed on 2026-03-31 09:00:13

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 15:43:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:39:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:38:38

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:37:37

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:36:09

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:34:15

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:32:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:31:28

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:30:05

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:28:33

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 20:26:35

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$453.60

28.6%

Avg:

$360.65

2.3%

Low:

$202.00

-42.7%

(% change is relative to the current stock price: $352.65)

Analyst Recommendations

Go to Analyst Tab

3.55

Good

14%

Strong Buy (6)

36%

Buy (15)

43%

Hold (18)

5%

Sell (2)

2%

Strong Sell (1)

About

Website
https://www.amgen.com/
Address
One Amgen Center Drive, Thousand Oaks CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=318154

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

IPO Date

1983-06-17

Industry

Biotechnology

Total Employees

31,500

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences